These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study. Sarris J; Oliver G; Camfield DA; Dean OM; Dowling N; Smith DJ; Murphy J; Menon R; Berk M; Blair-West S; Ng CH CNS Drugs; 2015 Sep; 29(9):801-9. PubMed ID: 26374743 [TBL] [Abstract][Full Text] [Related]
3. N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study. Li F; Welling MC; Johnson JA; Coughlin C; Mulqueen J; Jakubovski E; Coury S; Landeros-Weisenberger A; Bloch MH J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):32-37. PubMed ID: 31800306 [No Abstract] [Full Text] [Related]
5. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. Berlin HA; Koran LM; Jenike MA; Shapira NA; Chaplin W; Pallanti S; Hollander E J Clin Psychiatry; 2011 May; 72(5):716-21. PubMed ID: 20816027 [TBL] [Abstract][Full Text] [Related]
6. N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial. Sarris J; Byrne G; Castle D; Bousman C; Oliver G; Cribb L; Blair-West S; Brakoulias V; Camfield D; Ee C; Chamoli S; Boschen M; Dean OM; Dowling N; Menon R; Murphy J; Metri NJ; Nguyen TP; Wong A; Jordan R; Karamacoska D; Rossell SL; Berk M; Ng CH Prog Neuropsychopharmacol Biol Psychiatry; 2022 Jul; 117():110550. PubMed ID: 35304155 [TBL] [Abstract][Full Text] [Related]
7. Is mirtazapine augmentation effective for patients with obsessive-compulsive disorder who failed to respond to sertraline monotherapy? A placebo-controlled, double-blind, clinical trial. Mowla A; Baniasadipour H Int Clin Psychopharmacol; 2023 Jan; 38(1):4-8. PubMed ID: 35695582 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial. Storch EA; Wilhelm S; Sprich S; Henin A; Micco J; Small BJ; McGuire J; Mutch PJ; Lewin AB; Murphy TK; Geller DA JAMA Psychiatry; 2016 Aug; 73(8):779-88. PubMed ID: 27367832 [TBL] [Abstract][Full Text] [Related]
10. "N-Acetylcysteine for Obsessive-Compulsive and Related Disorders in Children and Adolescents: A Review". Parli GM; Gales MA; Gales BJ Ann Pharmacother; 2023 Jul; 57(7):847-854. PubMed ID: 36384314 [TBL] [Abstract][Full Text] [Related]
11. Pregabalin augmentation for resistant obsessive-compulsive disorder: a double-blind placebo-controlled clinical trial. Mowla A; Ghaedsharaf M CNS Spectr; 2020 Aug; 25(4):552-556. PubMed ID: 31648655 [TBL] [Abstract][Full Text] [Related]
12. Is quetiapine effective for obsessive and compulsive symptoms in patients with bipolar disorder? A randomized, double-blind, placebo-controlled clinical trial. Sahraian A; Ghahremanpouri B; Mowla A CNS Spectr; 2022 Oct; 27(5):634-638. PubMed ID: 34027853 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of adjunctive gabapentin and memantine in obsessive compulsive disorder: Double-blind, randomized, placebo-controlled trial. Farnia V; Gharehbaghi H; Alikhani M; Almasi A; Golshani S; Tatari F; Davarinejad O; Salemi S; Sadeghi Bahmani D; Holsboer-Trachsler E; Brand S J Psychiatr Res; 2018 Sep; 104():137-143. PubMed ID: 30044966 [TBL] [Abstract][Full Text] [Related]
14. Aripiprazole as an adjuvant treatment for obsessive and compulsive symptoms in manic phase of bipolar disorder: A randomized, double-blind, placebo-controlled clinical trial. Sahraian A; Ehsaei Z; Mowla A Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):267-271. PubMed ID: 29544694 [TBL] [Abstract][Full Text] [Related]
15. Memantine for Refractory Obsessive-Compulsive Disorder: Protocol for a Pragmatic, Double-blind, Randomized, Parallel-Group, Placebo-Controlled, Monocenter Trial. Maraone A; Trebbastoni A; Di Vita A; D'Antonio F; De Lena C; Pasquini M JMIR Res Protoc; 2023 May; 12():e39223. PubMed ID: 37166948 [TBL] [Abstract][Full Text] [Related]
17. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. Koran LM; Gamel NN; Choung HW; Smith EH; Aboujaoude EN J Clin Psychiatry; 2005 Apr; 66(4):515-20. PubMed ID: 15816795 [TBL] [Abstract][Full Text] [Related]
18. N-Acetylcysteine in the Treatment of Excoriation Disorder: A Randomized Clinical Trial. Grant JE; Chamberlain SR; Redden SA; Leppink EW; Odlaug BL; Kim SW JAMA Psychiatry; 2016 May; 73(5):490-6. PubMed ID: 27007062 [TBL] [Abstract][Full Text] [Related]
19. Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial. Afshar H; Akuchekian S; Mahaky B; Zarean E J Res Med Sci; 2014 Oct; 19(10):976-81. PubMed ID: 25538783 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. Carmi L; Tendler A; Bystritsky A; Hollander E; Blumberger DM; Daskalakis J; Ward H; Lapidus K; Goodman W; Casuto L; Feifel D; Barnea-Ygael N; Roth Y; Zangen A; Zohar J Am J Psychiatry; 2019 Nov; 176(11):931-938. PubMed ID: 31109199 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]